PerpEquities

AbbVie Inc. (ABBV) cash flow statement

NYSE · Healthcare · Drug Manufacturers - General · 57,000 employees · CEO Robert A. Michael

Price
$294.89 +1.41%
Market cap
$521B
Enterprise value
$585B
Last report
Q3 '26 filed 2026-09-30
Next report
2027-02-03 EPS est. $3.90

In Q2 '26 AbbVie Inc. (ABBV) generated $3.44B of operating cash flow, invested $322M in capital expenditure and kept $3.11B of free cash flow. Over the last four quarters free cash flow was –.

Cash flow

Cash flowTrendQ3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Operating
Net income$1.78B$826M$1.36B$1.37B$1.59B-$23M$1.29B$941M$188M$1.82B$697M$3.62B
Depreciation & amortization$2.24B$2.08B$2.07B$2.13B$2.08B$2.1B$2.04B$2.05B$2.06B$1.99B$1.94B$1.88B
Stock-based compensation$130M$125M$348M$218M$181M$164M$410M$179M$209M$157M$444M$166M
Deferred income tax-$863M-$1.39B-$389M-$16M-$277M-$767M-$28M-$272M$193M-$385M$137M-$195M
Change in working capital$2.64B$443M$247M-$3.38B$750M-$397M-$2.58B-$562M$1.25B-$473M-$1.92B-$2.72B
Other non-cash items$1.65B$2.67B$401M$1.95B$1.12B$5.97B$505M$2.82B$3.12B$2.13B$2.54B$687M
Operating cash flow$7.57B$4.75B$4.04B$2.27B$5.45B$7.05B$1.64B$5.15B$7.02B$5.22B$3.83B$3.44B
Investing
Capital expenditure-$219M-$205M-$193M-$241M-$249M-$291M-$235M-$269M-$381M-$329M-$265M-$322M
Acquisitions-$157M-$553M-$9.39B-$843M-$8.29B-$1.79B-$538M-$940M-$2.8B-$1.16B$0-$824M
Purchases of investments-$8M-$34M-$6M-$16M-$24M-$27M-$10M-$12M-$7M-$6M-$266M$0
Sales / maturities of investments$5M$14M$6M$3M$507M$39M$32M$7M$3M$34M$0$0
Other investing$10M-$22M-$6M-$5M-$196M$197M$16M$33M-$77M-$1M-$43M-$51M
Investing cash flow-$369M-$800M-$9.59B-$1.1B-$8.26B-$1.87B-$735M-$1.18B-$3.26B-$1.46B-$574M-$1.2B
Financing
Net debt issued / repaid-$2M-$1.79B$14.9B-$3.35B-$403M-$3.76B$2.56B$209M-$1.78B-$1.3B$5.49B-$2B
Share buybacks-$4M-$3M-$1.32B-$9M-$17M-$358M-$961M-$12M-$4M-$3M-$1.49B-$9M
Dividends-$2.63B-$2.63B-$2.77B-$2.75B-$2.75B-$2.75B-$2.93B-$2.91B-$2.91B-$2.91B-$3.09B-$3.07B
Other financing (incl. tax on vested shares)-$28M-$26M$52M$10M$99M$11M$67M$3M$37M-$1M$2M$25M
Financing cash flow-$2.66B-$4.45B$10.8B-$6.1B-$3.07B-$6.86B-$1.26B-$2.71B-$4.59B-$4.17B$919M-$5.05B
Summary
FX effect on cash-$16M$23M-$18M-$9M$8M-$46M$9M$30M-$8M$11M-$12M-$7M
Net change in cash$4.53B-$473M$5.25B-$4.94B-$5.87B-$1.73B-$349M$1.29B-$838M-$400M$4.16B-$2.82B
Free cash flow (OCF - capex)$7.36B$4.55B$3.85B$2.03B$5.2B$6.76B$1.4B$4.88B$6.64B$4.89B$3.56B$3.11B
Interest paid$0$0$0$0$0$705M$0$0$0$0$0$0

Standardised by Financial Modeling Prep from the company's filings; outflows and costs keep the sign the provider reports. Hover a period for its end date. Amounts in USD.

Operating cash flow, capex, free cash flow

quarterly

Uses of cash vs operating cash flow

fiscal years

Share count and EPS

quarterly, diluted

The other statements

Sources

Statements, segment revenue, metrics, estimates: Financial Modeling Prep. Segment profits and every reported line: SEC EDGAR (XBRL). Filings read: 10-Q 2026-06-30, 10-Q 2026-03-31, 10-K 2025-12-31, 10-Q 2025-09-30, 10-Q 2025-06-30, 10-Q 2025-03-31, 10-K 2024-12-31, 10-Q 2024-09-30, 10-Q 2024-06-30

Data as of 2026-11-01